ClinicalTrials.gg
RecruitingNCT05594511Updated May 25, 2023

Mandibular Muscle Energy Technique in Patients With Mandibular Joint Pathology and Bruxism

An interventional study of Muscle-energy mandibular technique and Sham technique in Temporomandibular Joint Disorders, Bruxism and Pain Threshold, sponsored by University of Salamanca. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-05-25.

Sponsored by University of Salamanca · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2023, 3 years 4 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Apr 2022, registered Oct 2022).
  • Started Apr 2022; still recruiting 4 years 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a randomized, controlled, double-blind clinical trial. The main objective is to evaluate the immediate effect of the mandibular muscle-energy technique on pain, functionality and kinesiophobia in subjects suffering from temporomandibular dysfunction and bruxism.

In the experimental group the jaw muscle-energy technique will be applied and in the control group a placebo technique will be applied. The intention is to see the immediate effects of the intervention and two evaluations of the pre- and post-intervention outcome variables and a follow-up of kinesiophobia one week later will be performed.

02

Conditions studied

  • Temporomandibular Joint Disorders
  • Bruxism
  • Pain Threshold
  • Kinesiophobia
03

In context

Temporomandibular Joint Disorders

591 studies on the registry are indexed under Temporomandibular Joint Disorders; 149 are open to participants now.

This study's planned enrollment of 60 is above the median of 45 across 415 interventional studies indexed under Temporomandibular Joint Disorders.

Browse Temporomandibular Joint Disorders studies →

Lead sponsor

University of Salamanca is the lead sponsor of 112 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who agree to participate in the study by signing the form.
  • Patients attending maxillofacial consultation with pain, temporomandibular dysfunction and bruxism.
  • Pain of at least 3 months of evolution.

Exclusion criteria

Exclusion Criteria:

  • Patients with congenital malformations or cervical spine pathology.
  • Infectious or inflammatory disease in its acute phase.
  • Patients with vertigo or vestibular alterations.
  • If there is a to the technique or phobia on the part of the patient.
  • Physiotherapy treatment (manual therapy or electrotherapy) in the last month before their incorporation in the study.
  • Pharmacological treatment (analgesics, relaxants and anti-inflammatory drugs) in the last 24 hours before the initial evaluation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Experimental Group (muscle-energy technique)

    Mandibular muscle energy technique: In the supine position, the patient will open the mouth and perform isometric contractions for closure controlled by the physiotherapist. Passively, the physiotherapist will increase the range of mandibular opening. The technique consists of performing 3 sets, with 3 isometric contractions in each set of 3 seconds each. At the end of each set, the physiotherapist will passively try to gain mouth opening in order to continue the rest of the sets. At the end of all sets, gently return to the resting position.

    Procedure: Muscle-energy mandibular technique

  • Sham comparator
    Control Group (sham technique)

    Sham technique: In the supine position, the physiotherapist will place his hands under the patient's skull with the fingertips in contact with the suboccipital musculature for 5 minutes, without applying pressure or therapeutic intent. The objective is to provide a stimulus as similar as possible to the original Suboccipital Inhibition Technique, but without force of movement. The patient will keep the eyes closed for the duration of the technique.

    Procedure: Sham technique

Interventions

  • ProcedureMuscle-energy mandibular technique

    A single session will be used with the mandibular musculoenergy technique. It will last approximately 2-3 minutes and will be performed by a physiotherapist.

  • ProcedureSham technique

    A single session with a sham technique simulating the suboccipital muscle inhibition technique will be used. It will last approximately 2-3 minutes and will be performed by a physiotherapist.

06

What researchers measure

Primary outcomes

  1. Changes in craniofacial pain intensity

    For the subjective evaluation of craniofacial pain, the visual analog scale (VAS) will be applied. Scale from 0 (no pain at all) to 10 (maximum possible pain).

    Time frame: 2 evaluations, one pre-intervention and one post-intervention, 5 minutes after the end of the intervention according to the assigned group.

Secondary outcomes

  1. Changes in mouth opening mobility

    The active opening of the mouth will be measured using a digital caliper

    Time frame: 2 evaluations, one pre-intervention and one post-intervention, 5 minutes after the end of the intervention according to the assigned group.

  2. Changes in rightward mandibular translation

    The active rightward mandibular translation will be measured using a digital caliper

    Time frame: 2 evaluations, one pre-intervention and one post-intervention, 5 minutes after the end of the intervention according to the assigned group.

  3. Changes in leftward mandibular translation

    The active leftward mandibular translation will be measured using a digital caliper

    Time frame: 2 evaluations, one pre-intervention and one post-intervention, 5 minutes after the end of the intervention according to the assigned group.

  4. Changes in Pressure pain threshold at myofascial trigger point (PT1) of the both upper trapezius muscles

    The pressure threshold will be recorded using a digital algometer

    Time frame: 2 evaluations, one pre-intervention and one post-intervention, 5 minutes after the end of the intervention according to the assigned group.

  5. Changes in pressure pain threshold at myofascial trigger point of the both external pterygoid muscles

    The pressure threshold will be recorded using a digital algometer

    Time frame: 2 evaluations, one pre-intervention and one post-intervention, 5 minutes after the end of the intervention according to the assigned group.

  6. Changes in pressure pain threshold at myofascial trigger point of the both digastric muscles

    The pressure threshold will be recorded using a digital algometer

    Time frame: 2 evaluations, one pre-intervention and one post-intervention, 5 minutes after the end of the intervention according to the assigned group.

  7. Changes in kinesiophobia

    The Kinesiophobia will be recorded using the spanish version of the Tampa Scale for Kinesiophobia for Temporomandibular Disorders (TSK-TMD-S). It is a valid and reliable instrument for measuring kinesiophobia in patients with TMD, and it uses a Likert scale (1-4) containing 11 items in 2 domains, with higher scores indicating higher levels of kinesiophobia (0-44).

    Time frame: 2 evaluations, one pre-intervention and one post-intervention, 5 minutes after the end of the intervention according to the assigned group. And a follow-up after one week

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Jun 2023, 13 months after the start.

Of 242 non-industry interventional studies with no phase under Temporomandibular Joint Disorders, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 21. This study's planned 13 months is above that.

Counting every sponsor, half of 246 studies reached it within 10 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2022
First posted
Oct 26, 2022
StartActual
Apr 25, 2022
Primary completionEst.
Jun 23, 2023
CompletionEst.
Jun 23, 2023
Last update
May 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05594511
Collaborators
Instituto de Investigación Biomédica de Salamanca
Responsible party
Roberto Méndez Sánchez (Professor, PhD, University of Salamanca) — Principal investigator
First posted
Oct 26, 2022
Start date
Apr 25, 2022
Primary completion
Jun 23, 2023 (estimated)
Completion
Jun 23, 2023 (estimated)
Last update
May 25, 2023

Study contacts

Roberto Méndez-Sánchez, PhD
Contact
ro_mendez@usal.es
+34 923294500 ext. 3201
Roberto Méndez-Sánchez, PhD
principal investigator · University of Salamanca
Antonio Márquez-Vera, PT
principal investigator · Institute for Biomedical Research of Salamanca

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion